Microenvironment and radiation therapy

BioMed Research International

Volumn 2013, Issue , 2013, Pages

  Yoshimura, Michio ^a   Itasaka, Satoshi ^a   Harada, Hiroshi ^a   Hiraoka, Masahiro ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACRIFLAVINE; ANGIOSTATIN; BEVACIZUMAB; CAPECITABINE; CARBOGEN; CEDIRANIB; DOXORUBICIN; ECHINOMYCIN; EVEROLIMUS; FLUOROURACIL; FUMAGILLOL CHLOROACETYLCARBAMATE; GEMCITABINE; HEMOGLOBIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 1BETA; LIFICIGUAT; MISONIDAZOLE; MONOCLONAL ANTIBODY DC101; NICOTINAMIDE; NIMORAZOLE; PROTEIN TYROSINE KINASE INHIBITOR; RAPAMYCIN; RECOMBINANT ENDOSTATIN; RECOMBINANT ERYTHROPOIETIN; SU 11657; TEMSIROLIMUS; TIRAPAZAMINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VATALANIB; ANGIOGENESIS INHIBITOR; ENDOSTATIN; HYPOXIA INDUCIBLE FACTOR 1; RADIOSENSITIZING AGENT; VASCULOTROPIN RECEPTOR;

ABSENCE OF SIDE EFFECTS; ACUTE TUMOR HYPOXIA; ADJUVANT CHEMORADIOTHERAPY; ADVANCED CANCER; ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BLADDER CANCER; BREAST CARCINOMA; CANCER CELL; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CELL HYPOXIA; CHRONIC TUMOR HYPOXIA; COLON TUMOR; COLORECTAL CANCER; CYTOTOXICITY; ENDOTHELIUM CELL; ERYTHROCYTE TRANSFUSION; GLIOBLASTOMA; HEAD AND NECK CANCER; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERBARIC OXYGEN; HYPOXIC CELL; LARYNX CANCER; LUNG CANCER; LUNG NON SMALL CELL CANCER; MULTIMODALITY CANCER THERAPY; NASOPHARYNX CARCINOMA; NEOPLASM; NONHUMAN; OUTCOME ASSESSMENT; OXYGEN DELIVERY DEVICE; OXYGEN TRANSPORT; PANCREAS CANCER; PERIPHERAL NEUROPATHY; PHARYNX CANCER; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; RADIOSENSITIVITY; RECTUM CANCER; REVIEW; THERAPY EFFECT; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; ANIMAL; ANOXIA; CLINICAL TRIAL (TOPIC); DRUG ANTAGONISM; METABOLISM; METHODOLOGY; MOUSE; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; RADIOTHERAPY;

ANGIOGENESIS INHIBITORS; ANIMALS; ANOXIA; CLINICAL TRIALS AS TOPIC; ENDOSTATINS; HEMOGLOBINS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; MICE; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; RADIATION-SENSITIZING AGENTS; RADIOTHERAPY; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; TUMOR MICROENVIRONMENT;

EID: 84874607439     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2013/685308     Document Type: Review

References (132)

1. Harada H., Hiraoka M., Hypoxia-inducible factor 1 in tumor radioresistance. Current Signal Transduction Therapy 2010 5 3 188 196 2-s2.0-78650191972 10.2174/157436210791920229
2. Kizaka-Kondoh S., Inoue M., Harada H., Hiraoka M., Tumor hypoxia: a target for selective cancer therapy. Cancer Science 2003 94 12 1021 1028 2-s2.0-0347029631 10.1111/j.1349-7006.2003.tb01395.x (Pubitemid 38035514)
3. Thomlinson R. H., Gray L. H., The histological structure of some human lung cancers and the possible implications for radiotherapy. British Journal of Cancer 1955 9 539 549
4. Vaupel P., Kallinowski F., Okunieff P., Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Research 1989 49 23 6449 6465 2-s2.0-0024408986 (Pubitemid 20008770)
5. 2 histography. Antioxidants & Redox Signaling 2007 9 8 1221 1235 2-s2.0-34447506424 10.1089/ars.2007.1628 (Pubitemid 47080831)
6. 2 tension measurements. Cancer Research 1991 51 12 3316 3322 2-s2.0-0025807618
7. Brown J. M., Wilson W. R., Exploiting tumour hypoxia in cancer treatment. Nature Reviews Cancer 2004 4 6 437 447 2-s2.0-2942590732 (Pubitemid 38745529)
8. Aebersold D. M., Burri P., Beer K. T., Laissue J., Djonov V., Greiner R. H., Semenza G. L., Expression of hypoxia-inducible factor-1 α: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Research 2001 61 7 2911 2916 2-s2.0-0035300410 (Pubitemid 32691934)
9. Nordsmark M., Overgaard M., Overgaard J., Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiotherapy and Oncology 1996 41 1 31 39 2-s2.0-0029955072 10.1016/S0167-8140(96)91811-3 (Pubitemid 26396294)
10. Brown J. M., Evidence for acutely hypoxic cells in mouse tumours, and a possible mechanism of reoxygenation. British Journal of Radiology 1979 52 620 650 656 2-s2.0-0018760476 (Pubitemid 9239867)
11. Hanahan D., Weinberg R. A., Hallmarks of cancer: the next generation. Cell 2011 144 5 646 674 2-s2.0-79952284127 10.1016/j.cell.2011.02.013
12. Jain R. K., Molecular regulation of vessel maturation. Nature Medicine 2003 9 6 685 693 2-s2.0-0038376002 10.1038/nm0603-685 (Pubitemid 36749217)
13. Hall E. J., Radiobiology for the Radiologists 1994 4th Philadelphia, Pa, USA J.B. Lippincott
14. Harada H., How can we overcome tumor hypoxia in radiation therapy. Journal of Radiation Research 2011 52 545 556
15. Dewhirst M. W., Relationships between cycling hypoxia, HIF-1, angiogenesis and oxidative stress. Radiation Research 2009 172 6 653 665 2-s2.0-70549102512 10.1667/RR1926.1
16. Dewhirst M. W., Cao Y., Moeller B., Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nature Reviews Cancer 2008 8 6 425 437 2-s2.0-44349157832 10.1038/nrc2397 (Pubitemid 351744964)
17. Gray L. H., Conger A. D., Ebert M., Hornsey S., Scott O. C., The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. British Journal of Radiology 1953 26 638 648
18. Moeller B. J., Cao Y., Li C. Y., Dewhirst M. W., Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. Cancer Cell 2004 5 5 429 441 2-s2.0-2342611976 10.1016/S1535-6108(04)00115-1 (Pubitemid 38610245)
19. Moeller B. J., Dewhirst M. W., HIF-1 and tumour radiosensitivity. British Journal of Cancer 2006 95 1 1 5 2-s2.0-33745517944 10.1038/sj.bjc.6603201 (Pubitemid 43980546)
20. Moeller B. J., Dreher M. R., Rabbani Z. N., Schroeder T., Cao Y., Li C. Y., Dewhirst M. W., Pleiotropic effects of HIF-1 blockade on tumor radiosensitivity. Cancer Cell 2005 8 2 99 110 2-s2.0-23644453277 10.1016/j.ccr.2005.06.016 (Pubitemid 41132739)
21. Hirota K., Semenza G. L., Regulation of hypoxia-inducible factor 1 by prolyl and asparaginyl hydroxylases. Biochemical and Biophysical Research Communications 2005 338 1 610 616 2-s2.0-27544504817 10.1016/j.bbrc.2005.08.193 (Pubitemid 41540610)
22. 2-regulated prolyl hydroxylation. Science 2001 292 5516 468 472 2-s2.0-0035917808 (Pubitemid 32335942)
23. Maxwell P. H., Wlesener M. S., Chang G. W., Clifford S. C., Vaux E. C., Cockman M. E., Wykoff C. C., Pugh C. W., Maher E. R., Ratcliffe P. J., The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999 399 6733 271 275 2-s2.0-0033587146 10.1038/20459 (Pubitemid 29246458)
24. 2 and the 3 PHDs: how animal cells signal hypoxia to the nucleus. Cell 2001 107 1 1 3 2-s2.0-0035812772 10.1016/S0092-8674(01)00518-9 (Pubitemid 32972030)
25. Semenza G. L., Regulation of cancer cell metabolism by hypoxia-inducible factor 1. Seminars in Cancer Biology 2009 19 1 12 16 2-s2.0-60549083256 10.1016/j.semcancer.2008.11.009
26. Chan D. A., Giaccia A. J., Hypoxia, gene expression, and metastasis. Cancer and Metastasis Reviews 2007 26 2 333 339 2-s2.0-34547125574 10.1007/s10555-007-9063-1 (Pubitemid 47101666)
27. Sullivan R., Graham C. H., Hypoxia-driven selection of the metastatic phenotype. Cancer and Metastasis Reviews 2007 26 2 319 331 2-s2.0-34547107592 10.1007/s10555-007-9062-2 (Pubitemid 47101665)
28. Forsythe J. A., Jiang B. H., Iyer N. V., Agani F., Leung S. W., Koos R. D., Semenza G. L., Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Molecular and Cellular Biology 1996 16 9 4604 4613 2-s2.0-0029761644 (Pubitemid 26272112)
29. Liao D., Johnson R. S., Hypoxia: a key regulator of angiogenesis in cancer. Cancer and Metastasis Reviews 2007 26 2 281 290 2-s2.0-34547124062 10.1007/s10555-007-9066-y (Pubitemid 47101669)
30. 2-independent and HSP90 inhibitor-induced degradation of HIF-1 α Molecular Cell 2007 25 2 207 217 2-s2.0-33846254999 10.1016/j.molcel. 2007.01.001 (Pubitemid 46109612)
31. Laughner E., Taghavi P., Chiles K., Mahon P. C., Semenza G. L., HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1 α (HIF-1 α) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Molecular and Cellular Biology 2001 21 12 3995 4004 2-s2.0-0035012605 10.1128/MCB.21.12.3995-4004.2001 (Pubitemid 32476461)
32. Zundel W., Schindler C., Haas-Kogan D., Koong A., Kaper F., Chen E., Gottschalk A. R., Ryan H. E., Johnson R. S., Jefferson A. B., Stokoe D., Giaccia A. J., Loss of PTEN facilitates HIF-1-mediated gene expression. Genes and Development 2000 14 4 391 396 2-s2.0-0034050050 (Pubitemid 30131884)
33. Mahon P. C., Hirota K., Semenza G. L., FIH-1: a novel protein that interacts with HIF-1 α and VHL to mediate repression of HIF-1 transcriptional activity. Genes and Development 2001 15 20 2675 2686 2-s2.0-0035887011 10.1101/gad.924501 (Pubitemid 32988878)
34. Harada H., Itasaka S., Kizaka-Kondoh S., Shibuya K., Morinibu A., Shinomiya K., Hiraoka M., The Akt/mTOR pathway assures the synthesis of HIF-1 α protein in a glucose- and reoxygenation-dependent manner in irradiated tumors. The Journal of Biological Chemistry 2009 284 8 5332 5342 2-s2.0-64149112403 10.1074/jbc.M806653200
35. Harada H., Itasaka S., Zhu Y., Zeng L., Xie X., Morinibu A., Shinomiya K., Hiraoka M., Treatment regimen determines whether an HIF-1 inhibitor enhances or inhibits the effect of radiation therapy. British Journal of Cancer 2009 100 5 747 757 2-s2.0-61749090849 10.1038/sj.bjc.6604939
36. Gorski D. H., Beckett M. A., Jaskowiak N. T., Calvin D. P., Mauceri H. J., Salloum R. M., Seetharam S., Koons A., Hari D. M., Kufe D. W., Weichselbaum R. R., Blockade of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Research 1999 59 14 3374 3378 2-s2.0-0033564974 (Pubitemid 29334495)
37. Zeng L., Ou G., Itasaka S., Harada H., Xie X., Shibuya K., Kizaka-Kondoh S., Morinibu A., Shinomiya K., Hiraoka M., TS-1 enhances the effect of radiotherapy by suppressing radiation-induced hypoxia-inducible factor-1 activation and inducing endothelial cell apoptosis. Cancer Science 2008 99 11 2327 2335 2-s2.0-55449136468 10.1111/j.1349-7006.2008.00943.x
38. Harada H., Kizaka-Kondoh S., Li G., Itasaka S., Shibuya K., Inoue M., Hiraoka M., Significance of HIF-1-active cells in angiogenesis and radioresistance. Oncogene 2007 26 54 7508 7516 2-s2.0-36749029349 10.1038/sj.onc.1210556 (Pubitemid 350207705)
39. Li F., Sonveaux P., Rabbani Z. N., Liu S., Yan B., Huang Q., Vujaskovic Z., Dewhirst M., Li C. Y., Regulation of HIF-1 α stability through S-nitrosylation. Molecular Cell 2007 26 1 63 74 2-s2.0-34047272690 10.1016/j.molcel.2007.02.024 (Pubitemid 46550936)
40. Ou G., Itasaka S., Zeng L., Shibuya K., Yi J., Harada H., Hiraoka M., Usefulness of HIF-1 imaging for determining optimal timing of combining bevacizumab and radiotherapy. International Journal of Radiation Oncology, Biology, Physics 2009 75 2 463 467 2-s2.0-69549122382 10.1016/j.ijrobp.2009.02. 083
41. Harada H., Inoue M., Itasaka K S., Cancer cells that survive radiation therapy acquire HIF-1 activity and translocate towards tumour blood vessels. Nature Communications 2012 3, article 783
42. Folkman J., Tumor angiogenesis: therapeutic implications. The New England Journal of Medicine 1971 285 21 1182 1186 2-s2.0-0015231516
43. Kozin S. V., Boucher Y., Hicklin D. J., Bohlen P., Jain R. K., Suit H. D., Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts. Cancer Research 2001 61 1 39 44 2-s2.0-0035132923 (Pubitemid 32095696)
44. Huber P. E., Bischof M., Jenne J., Heiland S., Peschke P., Saffrich R., Gröne H. J., Debus J., Lipson K. E., Abdollahi A., Trimodal cancer treatment: beneficial effects of combined antiangiogenesis, radiation, and chemotherapy. Cancer Research 2005 65 9 3643 3655 2-s2.0-20944448672 10.1158/0008-5472.CAN-04-1668 (Pubitemid 40616341)
45. Mauceri H. J., Hanna N. N., Beckett M. A., Gorski D. H., Staba M. J., Stellato K. A., Bigelow K., Heimann R., Gately S., Dhanabal M., Soff G. A., Sukhatme V. P., Kufe D. W., Weichselbaum R. R., Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature 1998 394 6690 287 291 2-s2.0-18244419396 10.1038/28412 (Pubitemid 28335042)
46. Gorski D. H., Mauceri H. J., Salloum R. M., Gately S., Hellman S., Beckett M. A., Sukhatme V. P., Soff G. A., Kufe D. W., Weichselbaum R. R., Potentiation of the antitumor effect of ionizing radiation by brief concomitant exposures to angiostatin. Cancer Research 1998 58 24 5686 5689 2-s2.0-17444376781 (Pubitemid 29006406)
47. Griscelli F., Li H., Cheong C., Opolon P., Bennaceur-Griscelli A., Vassal G., Soria J., Soria C., Lu H., Perricaudet M., Yeh P., Combined effects of radiotherapy and angiostatin gene therapy in glioma tumor model. Proceedings of the National Academy of Sciences of the United States of America 2000 97 12 6698 6703 2-s2.0-12944331952 10.1073/pnas.110134297 (Pubitemid 30412777)
48. Hanna N. N., Seetharam S., Mauceri H. J., Beckett M. A., Jaskowiak N. T., Salloum R. M., Hari D., Dhanabal M., Ramchandran R., Kalluri R., Sukhatme V. P., Kufe D. W., Weichselbaum R. R., Antitumor interaction of short-course endostatin and ionizing radiation. Cancer Journal 2000 6 5 287 293 2-s2.0-0033758044
49. Itasaka S., Komaki R., Herbst R. S., Shibuya K., Shintani T., Hunter N. R., Onn A., Bucana C. D., Milas L., Ang K. K., O'Reilly M. S., Endostatin improves radioresponse and blocks tumor revascularization after radiation therapy for A431 xenografts in mice. International Journal of Radiation Oncology, Biology, Physics 2007 67 3 870 878 2-s2.0-33846785143 10.1016/j.ijrobp.2006.10.030 (Pubitemid 46215889)
50. Peng F., Xu Z., Wang J., Chen Y., Li Q., Zuo Y., Chen J., Hu X., Zhou Q., Wang Y., Ma H., Bao Y., Chen M., Recombinant human endostatin normalizes tumor vasculature and enhances radiation response in xenografted human nasopharyngeal carcinoma models. PLoS One 2012 7 e34646
51. Murata R., Nishimura Y., Hiraoka M., An antiangiogenic agent (TNP-470) inhibited reoxygenation during fractionated radiotherapy of murine mammary carcinoma. International Journal of Radiation Oncology, Biology, Physics 1997 37 5 1107 1113 2-s2.0-0030971274 10.1016/S0360-3016(96)00628-1 (Pubitemid 27230036)
52. Dings R. P., Loren M., Heun H., McNiel E., Griffioen A. W., Mayo K. H., Griffin R. J., Scheduling of radiation with angiogenesis inhibitors anginex and avastin improves therapeutic outcome via vessel normalization. Clinical Cancer Research 2007 13 11 3395 3402 2-s2.0-34250660932 10.1158/1078-0432.CCR-06-2441 (Pubitemid 46944928)
53. Hoang T., Huang S., Armstrong E., Eickhoff J. C., Harari P. M., Enhancement of radiation response with bevacizumab. Journal of Experimental & Clinical Cancer Research 2012 31, article 37
54. Lee C. G., Heijn M., di Tomaso E., Griffon-Etienne G., Ancukiewicz M., Koike C., Park K. R., Ferrara N., Jain R. K., Suit H. D., Boucher Y., Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Research 2000 60 19 5565 5570 2-s2.0-0034306974
55. Winkler F., Kozin S. V., Tong R. T., Chae S. S., Booth M. F., Garkavtsev I., Xu L., Hicklin D. J., Fukumura D., Di Tomaso E., Munn L. L., Jain R. K., Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 2004 6 6 553 563 2-s2.0-19944422751 10.1016/j.ccr.2004.10.011 (Pubitemid 40017699)
56. Zips D., Hessel F., Krause M., Schiefer Y., Hoinkis C., Thames H. D., Haberey M., Baumann M., Impact of adjuvant inhibition of vascular endothelial growth factor receptor tyrosine kinases on tumor growth delay and local tumor control after fractionated irradiation in human squamous cell carcinomas in nude mice. International Journal of Radiation Oncology, Biology, Physics 2005 61 3 908 914 2-s2.0-13844266132 10.1016/j.ijrobp.2004.11.007 (Pubitemid 40247990)
57. Hess C., Vuong V., Hegyi I., Riesterer O., Wood J., Fabbro D., Glanzmann C., Bodis S., Pruschy M., Effect of VEGF receptor inhibitor PTK787/ZK222548 combined with ionizing radiation on endothelial cells and tumour growth. British Journal of Cancer 2001 85 12 2010 2016 2-s2.0-0035555907 (Pubitemid 34775341)
58. Williams K. J., Telfer B. A., Brave S., Kendrew J., Whittaker L., Stratford I. J., Wedge S. R., ZD6474, a potent inhibitor of vascular endothelial growth factor signaling, combined with radiotherapy: schedule-dependent enhancement of antitumor activity. Clinical Cancer Research 2004 10 24 8587 8593 2-s2.0-11144223542 10.1158/1078-0432.CCR-04-1147 (Pubitemid 40053426)
59. Shibuya K., Komaki R., Shintani T., Itasaka S., Ryan A., Jürgensmeier J. M., Milas L., Ang K., Herbst R. S., O'Reilly M. S., Targeted therapy against VEGFR and EGFR with ZD6474 enhances the therapeutic efficacy of irradiation in an orthotopic model of human non-small-cell lung cancer. International Journal of Radiation Oncology, Biology, Physics 2007 69 5 1534 1543 2-s2.0-36149001692 10.1016/j.ijrobp.2007.07.2350 (Pubitemid 350116420)
60. Cao C., Albert J. M., Geng L., Ivy P. S., Sandler A., Johnson D. H., Lu B., Vascular endothelial growth factor tyrosine kinase inhibitor AZD2171 and fractionated radiotherapy in mouse models of lung cancer. Cancer Research 2006 66 23 11409 11415 2-s2.0-33845780061 10.1158/0008-5472.CAN-06-2414 (Pubitemid 46009972)
61. Williams K. J., Telfer B. A., Shannon A. M., Babur M., Stratford I. J., Wedge S. R., Combining radiotherapy with AZD2171, a potent inhibitor of vascular endothelial growth factor signaling: pathophysiologic effects and therapeutic benefit. Molecular Cancer Therapeutics 2007 6 2 599 606 2-s2.0-33847344281 10.1158/1535-7163.MCT-06-0508 (Pubitemid 46332462)
62. Geng L., Donnelly E., McMahon G., Lin P. C., Sierra-Rivera E., Oshinka H., Hallahan D. E., Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy. Cancer Research 2001 61 6 2413 2419 2-s2.0-0035866771 (Pubitemid 32685816)
63. Ning S., Laird D., Cherrington J. M., Knox S. J., The antiangiogenic agents SU5416 and SU6668 increase the antitumor effects of fractionated irradiation. Radiation Research 2002 157 1 45 51 2-s2.0-0036145292 (Pubitemid 34073387)
64. Griffin R. J., Williams B. W., Wild R., Cherrington J. M., Park H., Song C. W., Simultaneous inhibition of the receptor kinase activity of vascular endothelial, fibroblast, and platelet-derived growth factors suppresses tumor growth and enhances tumor radiation response. Cancer Research 2002 62 6 1702 1706 2-s2.0-0037085933 (Pubitemid 34408492)
65. Cuneo K. C., Geng L., Fu A., Orton D., Hallahan D. E., Chakravarthy A. B., SU11248 (sunitinib) sensitizes pancreatic cancer to the cytotoxic effects of ionizing radiation. International Journal of Radiation Oncology, Biology, Physics 2008 71 3 873 879 2-s2.0-44349119079 10.1016/j.ijrobp.2008.02.062 (Pubitemid 351749533)
66. Schueneman A. J., Himmelfarb E., Geng L., Tan J., Donnelly E., Mendel D., McMahon G., Hallahan D. E., SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models. Cancer Research 2003 63 14 4009 4016 2-s2.0-0041672482 (Pubitemid 36917920)
67. Teicher B. A., Holden S. A., Ara G., Dupuis N. P., Liu F., Yuan J., Ikebe M., Kakeji Y., Influence of an anti-angiogenic treatment on 9L gliosarcoma: oxygenation and response to cytotoxic therapy. International Journal of Cancer 1995 61 5 732 737 2-s2.0-0029069833 10.1002/ijc.2910610523
68. Lund E. L., Bastholm L., Kristjansen P. E., Therapeutic synergy of TNP-470 and ionizing radiation: effects on tumor growth, vessel morphology, and angiogenesis in human glioblastoma multiforme xenografts. Clinical Cancer Research 2000 6 3 971 978 2-s2.0-0034099423 (Pubitemid 30159356)
69. D'Amato R. J., Loughnan M. S., Flynn E., Folkman J., Thalidomide is an inhibitor of angiogenesis. Proceedings of the National Academy of Sciences of the United States of America 1994 91 9 4082 4085 2-s2.0-0028216334 (Pubitemid 24139577)
70. Garcia-Barros M., Paris F., Cordon-Cardo C., Lyden D., Rafii S., Haimovitz-Friedman A., Fuks Z., Kolesnick R., Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 2003 300 5622 1155 1159 2-s2.0-0038626211 10.1126/science.1082504 (Pubitemid 36583102)
71. Fletcher G. H., Lindberg R. D., Caderao J. B., Wharton J. T., Hyperbaric oxygen as a radiotherapeutic adjuvant in advanced cancer of the uterine cervix: preliminary results of a randomized trial. Cancer 1977 39 2 617 623 2-s2.0-0017325320 (Pubitemid 8063529)
72. Watson E. R., Halnan K. E., Dische S., Hyperbaric oxygen and radiotherapy: A Medical Research Council trial in carcinoma of the cervix. British Journal of Radiology 1978 51 611 879 887 2-s2.0-0018123111 (Pubitemid 9033490)
73. Brady L. W., Plenk H. P., Hanley J. A., Glassburn J. R., Kramer S., Parker R. G., Hyperbaric oxygen therapy for carcinoma of the cervix-stages IIB, IIIA, IIIB and IVA: results of a randomized study by the radiation therapy oncology group. International Journal of Radiation Oncology, Biology, Physics 1981 7 8 991 998 2-s2.0-0019837689 (Pubitemid 12234144)
74. Hoskin P. J., Saunders M. I., Dische S., Hypoxic radiosensitizers in radical radiotherapy for patients with bladder carcinoma: hyperbaric oxygen, misonidazole, and accelerated radiotherapy, carbogen, and nicotinamide. Cancer 1999 86 1322 1328 (Pubitemid 29447018)
75. Haffty B. G., Hurley R., Peters L. J., Radiation therapy with hyperbaric oxygen at 4 atmospheres pressure in the management of squamous cell carcinoma of the head and neck: results of a randomized clinical trial. Cancer Journal from Scientific American 1999 5 6 341 347 2-s2.0-0033376853 (Pubitemid 30022426)
76. Beppu T., Kamada K., Nakamura R., Oikawa H., Takeda M., Fukuda T., Arai H., Ogasawara K., Ogawa A., A phase II study of radiotherapy after hyperbaric oxygenation combined with interferon-beta and nimustine hydrochloride to treat supratentorial malignant gliomas. Journal of Neuro-Oncology 2003 61 2 161 170 2-s2.0-0345270450 10.1023/A:1022169107872 (Pubitemid 36258337)
77. Surjana D., Halliday G. M., Damian D. L., Role of nicotinamide in DNA damage, mutagenesis, and DNA repair. Journal of Nucleic Acids 2010 2010 13 157591 10.4061/2010/157591
78. Albert J. M., Cao C., Kim K. W., Willey C. D., Geng L., Xiao D., Wang H., Sandler A., Johnson D. H., Colevas A. D., Low J., Rothenberg M. L., Lu B., Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models. Clinical Cancer Research 2007 13 10 3033 3042 2-s2.0-34249784216 10.1158/1078-0432.CCR-06-2872 (Pubitemid 46849580)
79. Calabrese C. R., Almassy R., Barton S., Batey M. A., Calvert A. H., Canan-Koch S., Durkacz B. W., Hostomsky Z., Kumpf R. A., Kyle S., Li J., Maegley K., Newell D. R., Notarianni E., Stratford I. J., Skalitzky D., Thomas H. D., Wang L. Z., Webber S. E., William K. J., Curtin N. J., Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. Journal of the National Cancer Institute 2004 96 1 56 67 2-s2.0-10744226451 (Pubitemid 38180960)
80. Khan K., Araki K., Wang D., Li G., Li X., Zhang J., Xu W., Hoover R. K., Lauter S., O'Malley B., Lapidus R. G., Li D., Head and neck cancer radiosensitization by the novel poly(ADP-ribose) polymerase inhibitor GPI-15427. Head & Neck 2010 32 3 381 391 2-s2.0-76249127431 10.1002/hed.21195
81. Mendenhall W. M., Morris C. G., Amdur R. J., Mendenhall N. P., Siemann D. W., Radiotherapy alone or combined with carbogen breathing for squamous cell carcinoma of the head and neck: a prospective, randomized trial. Cancer 2005 104 2 332 337 2-s2.0-22244488361 10.1002/cncr.21146 (Pubitemid 40993260)
82. Hoskin P. J., Rojas A. M., Saunders M. I., Bentzen S. M., Motohashi K. J., Carbogen and nicotinamide in locally advanced bladder cancer: early results of a phase-III randomized trial. Radiotherapy and Oncology 2009 91 1 120 125 2-s2.0-62549153550 10.1016/j.radonc.2008.10.001
83. Janssens G. O., Rademakers S. E., Terhaard C. H., Accelerated radiotherapy with carbogen and nicotinamide for laryngeal cancer: results of a phase III randomized trial. Journal of Clinical Oncology 2012 30 15 1777 1183
84. Vaupel P., Mayer A., Höckel M., Impact of hemoglobin levels on tumor oxygenation: the higher, the better? Strahlentherapie und Onkologie 2006 182 2 63 71 2-s2.0-31744438176 10.1007/s00066-006-1543-7 (Pubitemid 43177190)
85. Hoff C. M., Hansen H. S., Overgaard M., Grau C., Johansen J., Bentzen J., Overgaard J., The importance of haemoglobin level and effect of transfusion in HNSCC patients treated with radiotherapy-results from the randomized DAHANCA 5 study. Radiotherapy and Oncology 2011 98 1 28 33 2-s2.0-78651367214 10.1016/j.radonc.2010.09.024
86. Poskitt T. R., Radiation therapy and the role of red blood cell transfusion. Cancer Investigation 1987 5 3 231 236 2-s2.0-0023262969 (Pubitemid 17125580)
87. Pinel S., Barberi-Heyob M., Cohen-Jonathan E., Merlin J. L., Delmas C., Plenat F., Chastagner P., Erythropoietin-induced reduction of hypoxia before and during fractionated irradiation contributes to improvement of radioresponse in human glioma xenografts. International Journal of Radiation Oncology, Biology, Physics 2004 59 1 250 259 2-s2.0-11344268695 10.1016/j.ijrobp.2003.12.022 (Pubitemid 38501530)
88. Hoskin P. J., Robinson M., Slevin N., Morgan D., Harrington K., Gaffney C., Effect of epoetin alfa on survival and cancer treatment-related anemia and fatigue in patients receiving radical radiotherapy with curative intent for head and neck cancer. Journal of Clinical Oncology 2009 27 34 5751 5756 2-s2.0-73349123824 10.1200/JCO.2009.22.3693
89. Machtay M., Pajak T. F., Suntharalingam M., Shenouda G., Hershock D., Stripp D. C., Cmelak A. J., Schulsinger A., Fu K. K., Radiotherapy with or without erythropoietin for anemic patients with head and neck cancer: a randomized trial of the Radiation Therapy Oncology Group (RTOG 99-03). International Journal of Radiation Oncology, Biology, Physics 2007 69 4 1008 1017 2-s2.0-35448992197 10.1016/j.ijrobp.2007.04.063 (Pubitemid 47625834)
90. Baillet F., Housset M., Dessard-Diana B., Boisserie G., Positive clinical experience with misonidazole in brachytherapy and external radiotherapy. International Journal of Radiation Oncology, Biology, Physics 1989 16 4 1073 1075 2-s2.0-0024343498 (Pubitemid 19154305)
91. Minsky B. D., Leibel S. A., The treatment of hepatic metastases from colorectal cancer with radiation therapy alone or combined with chemotherapy or misonidazole. Cancer Treatment Reviews 1989 16 4 213 219 2-s2.0-0024957873 10.1016/0305-7372(89)90042-X (Pubitemid 20205942)
92. Overgaard J., Hansen H. S., Overgaard M., Bastholt L., Berthelsen A., Specht L., Lindeløv B., Jørgensen K., A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. Radiotherapy and Oncology 1998 46 2 135 146 2-s2.0-0031909654 10.1016/S0167-8140(97)00220-X (Pubitemid 28109172)
93. Simpson J. R., Bauer M., Perez C. A., Wasserman T. H., Emami B., Doggett R. L. S., Byhardt R. W., Phillips T. L., Mowry P. A., Radiation therapy alone or combined with misonidazole in the treatment of locally advanced non-oat cell lung cancer: report of an RTOG prospective randomized trial. International Journal of Radiation Oncology, Biology, Physics 1989 16 6 1483 1491 2-s2.0-0024322637 (Pubitemid 19154334)
94. Zeman E. M., Brown J. M., Lemmon M. J., Hirst V. K., Lee W. W., SR-4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells. International Journal of Radiation Oncology, Biology, Physics 1986 12 7 1239 1242 2-s2.0-0022493495 (Pubitemid 16055893)
95. Baker M. A., Zeman E. M., Hirst V. K., Brown J. M., Metabolism of SR 4233 by Chinese hamster ovary cells: basis of selective hypoxic cytotoxicity. Cancer Research 1988 48 21 5947 5952 2-s2.0-0023689603 (Pubitemid 18266781)
96. Zagorevskii D., Song M., Breneman C., Yuan Y., Fuchs T., Gates K. S., Greenlief C. M., A mass spectrometry study of tirapazamine and its metabolites: insights into the mechanism of metabolic transformations and the characterization of reaction intermediates. Journal of the American Society for Mass Spectrometry 2003 14 8 881 892 2-s2.0-0042348003 10.1016/S1044-0305(03) 00334-9 (Pubitemid 36904260)
97. Rischin D., Peters L., Fisher R., Macann A., Denham J., Poulsen M., Jackson M., Kenny L., Penniment M., Carry J., Lamb D., McClure B., Tirapazamine, cisplatin, and radiation versus fluorouracil, cisplatin, and radiation in patients with locally advanced head and neck cancer: a randomized phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02). Journal of Clinical Oncology 2005 23 1 79 87 2-s2.0-16644377045 10.1200/JCO.2005.01.072 (Pubitemid 41702625)
98. von Pawel J., von Roemeling R., Gatzemeier U., Boyer M., Elisson L. O., Clark P., Talbot D., Augustin R., Butler T. W., Hirsh V., Olver I., Bergman B., Ayoub J., Richardson G., Dunlop D., Arcenas A., Vescio R., Viallet J., Treat J., Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: a report of the international CATAPULT I study group. Journal of Clinical Oncology 2000 18 6 1351 1359 2-s2.0-0034104328 (Pubitemid 30159856)
99. Rischin D., Peters L. J., O'Sullivan B., Giralt J., Fisher R., Yuen K., Trotti A., Bernier J., Bourhis J., Ringash J., Henke M., Kenny L., Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, headstart): a phase III trial of the trans-tasman radiation oncology group. Journal of Clinical Oncology 2010 28 18 2989 2995 2-s2.0-77954600498 10.1200/JCO.2009.27.4449
100. Hicks K. O., Siim B. G., Jaiswal J. K., Pruijn F. B., Fraser A. M., Patel R., Hogg A., Liyanage H. D. S., Dorie M. J., Brown J. M., Denny W. A., Hay M. P., Wilson W. R., Pharmacokinetic/pharmacodynamic modeling identifies SN30000 and SN29751 as tirapazamine analogues with improved tissue penetration and hypoxic cell killing in tumors. Clinical Cancer Research 2010 16 20 4946 4957 2-s2.0-77958060317 10.1158/1078-0432.CCR-10-1439
101. Irie N., Matsuo T., Nagata I., Protocol of radiotherapy for glioblastoma according to the expression of HIF-1. Brain Tumor Pathology 2004 21 1 1 6 2-s2.0-3142672781 10.1007/BF02482169 (Pubitemid 38915175)
102. Ishikawa H., Sakurai H., Hasegawa M., Mitsuhashi N., Takahashi M., Masuda N., Nakajima M., Kitamoto Y., Saitoh J. I., Nakano T., Expression of hypoxic-inducible factor 1 α predicts metastasis-free survival after radiation therapy alone in stage IIIB cervical squamous cell carcinoma. International Journal of Radiation Oncology, Biology, Physics 2004 60 2 513 521 2-s2.0-4544276339 10.1016/j.ijrobp.2004.03.025 (Pubitemid 39233471)
103. Semenza G. L., Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 2010 29 5 625 634 2-s2.0-76349095132 10.1038/onc.2009.441
104. Shin D. H., Kim J. H., Jung Y. J., Kim K. E., Jeong J. M., Chun Y. S., Park J. W., Preclinical evaluation of YC-1, a HIF inhibitor, for the prevention of tumor spreading. Cancer Letters 2007 255 1 107 116 2-s2.0-34547660100 10.1016/j.canlet.2007.03.026 (Pubitemid 47212610)
105. Yeo E. J., Chun Y. S., Cho Y. S., Kim J., Lee J. C., Kim M. S., Park J. W., YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1. Journal of the National Cancer Institute 2003 95 7 516 525 2-s2.0-0037414180 (Pubitemid 36511622)
106. Gao P., Zhang H., Dinavahi R., Li F., Xiang Y., Raman V., Bhujwalla Z. M., Felsher D. W., Cheng L., Pevsner J., Lee L. A., Semenza G. L., Dang C. V., HIF-dependent antitumorigenic effect of antioxidants in vivo. Cancer Cell 2007 12 3 230 238 2-s2.0-34548257176 10.1016/j.ccr.2007.08.004 (Pubitemid 47333417)
107. Lee K., Zhang H., Qian D. Z., Rey S., Liu J. O., Semenza G. L., Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization. Proceedings of the National Academy of Sciences of the United States of America 2009 106 42 17910 17915 2-s2.0-70449580319 10.1073/pnas.0909353106
108. Zhong H., Chiles K., Feldser D., Laughner E., Hanrahan C., Georgescu M. M., Simons J. W., Semenza G. L., Modulation of hypoxia-inducible factor 1 α expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Research 2000 60 6 1541 1545 2-s2.0-0034654174 (Pubitemid 30183422)
109. Majumder P. K., Febbo P. G., Bikoff R., Berger R., Xue Q., McMahon L. M., Manolal J., Brugarolas J., J McDonnell T., Golub T. R., Loda M., Lane H. A., Sellers W. R., mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nature Medicine 2004 10 6 594 601 2-s2.0-2942724235 10.1038/nm1052 (Pubitemid 38796850)
110. Wysocki P. J., mTOR in renal cell cancer: modulator of tumor biology and therapeutic target. Expert Review of Molecular Diagnostics 2009 9 3 231 241 2-s2.0-66749114931 10.1586/erm.09.8
111. Wang R., Zhou S., Li S., Cancer therapeutic agents targeting hypoxia-inducible factor-1. Current Medicinal Chemistry 2011 18 21 3168 3189 2-s2.0-79959955993 10.2174/092986711796391606
112. Yasui H., Ogura A., Asanuma T., Matsuda A., Kashiwakura I., Kuwabara M., Inanami O., Inhibition of HIF-1 α by the anticancer drug TAS106 enhances X-ray-induced apoptosis in vitro and in vivo. British Journal of Cancer 2008 99 9 1442 1452 2-s2.0-55249116244 10.1038/sj.bjc.6604720
113. Schwartz D. L., Powis G., Thitai-Kumar A., He Y., Bankson J., Williams R., Lemos R., Oh J., Volgin A., Soghomonyan S., Nishii R., Alauddin M., Mukhopadhay U., Peng Z., Bornmann W., Gelovani J., The selective hypoxia inducible factor-1 inhibitor PX-478 provides in vivo radiosensitization through tumor stromal effects. Molecular Cancer Therapeutics 2009 8 4 947 958 2-s2.0-66449118481 10.1158/1535-7163.MCT-08-0981
114. Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., Heim W., Berlin J., Baron A., Griffing S., Holmgren E., Ferrara N., Fyfe G., Rogers B., Ross R., Kabbinavar F., Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. The New England Journal of Medicine 2004 350 23 2335 2342 2-s2.0-2542561964 10.1056/NEJMoa032691 (Pubitemid 38702844)
115. Sandler A., Gray R., Perry M. C., Brahmer J., Schiller J. H., Dowlati A.,
116. Willett C. G., Duda D. G., di Tomaso E., Boucher Y., Ancukiewicz M., Sahani D. V., Lahdenranta J., Chung D. C., Fischman A. J., Lauwers G. Y., Shellito P., Czito B. G., Wong T. Z., Paulson E., Poleski M., Vujaskovic Z., Bentley R., Chen H. X., Clark J. W., Jain R. K., Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. Journal of Clinical Oncology 2009 27 18 3020 3026 2-s2.0-67649921334 10.1200/JCO.2008.21.1771
117. Koukourakis M. I., Giatromanolaki A., Sheldon H., Buffa F. M., Kouklakis G., Ragoussis I., Sivridis E., Harris A. L., Phase I/II trial of bevacizumab and radiotherapy for locally advanced inoperable colorectal cancer: vasculature-independent radiosensitizing effect of bevacizumab. Clinical Cancer Research 2009 15 22 7069 7076 2-s2.0-72549116624 10.1158/1078-0432.CCR-09-0688
118. Crane C. H., Eng C., Feig B. W., Das P., Skibber J. M., Chang G. J., Wolff R. A., Krishnan S., Hamilton S., Janjan N. A., Maru D. M., Ellis L. M., Rodriguez-Bigas M. A., Phase II trial of neoadjuvant bevacizumab, capecitabine, and radiotherapy for locally advanced rectal cancer. International Journal of Radiation Oncology, Biology, Physics 2010 76 3 824 830 2-s2.0-76049088643 10.1016/j.ijrobp.2009.02.037
119. Crane C. H., Winter K., Regine W. F., Safran H., Rich T. A., Curran W., Wolff R. A., Willett C. G., Phase II study of bevacizumab with concurrent capecitabine and radiation followed by maintenance gemcitabine and bevacizumab for locally advanced pancreatic cancer: Radiation Therapy Oncology Group RTOG 0411. Journal of Clinical Oncology 2009 27 25 4096 4102 2-s2.0-70249130566 10.1200/JCO.2009.21.8529
120. Lee N. Y., Zhang Q., Pfister D. G., Kim J., Garden A. S., Mechalakos J., Hu K., Le Q. T., Colevas A. D., Glisson B. S., Chan A. T., Ang K. K., Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multi-institutional trial. The Lancet Oncology 2012 13 172 180
121. Narayana A., Gruber D., Kunnakkat S., Golfinos J. G., Parker E., Raza S., Zagzag D., Eagan P., Gruber M. L., A clinical trial of bevacizumab, temozolomide, and radiation for newly diagnosed glioblastoma. Journal of Neurosurgery 2012 116 341 345
122. Drappatz J., Norden A. D., Wong E. T., Doherty L. M., Lafrankie D. C., Ciampa A., Kesari S., Sceppa C., Gerard M., Phan P., Schiff D., Batchelor T. T., Ligon K. L., Young G., Muzikansky A., Weiss S. E., Wen P. Y., Phase I study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastoma. International Journal of Radiation Oncology, Biology, Physics 2010 78 1 85 90 2-s2.0-77955922743 10.1016/j.ijrobp.2009.07.1741
123. Kao J., Packer S., Vu H. L., Schwartz M. E., Sung M. W., Stock R. G., Lo Y. C., Huang D., Chen S. H., Cesaretti J. A., Phase 1 study of concurrent sunitinib and image-guided radiotherapy followed by maintenance sunitinib for patients with oligometastases: acute toxicity and preliminary response. Cancer 2009 115 15 3571 3580 2-s2.0-68149170060 10.1002/cncr.24412
124. Wuthrick E. J., Kamrava M., Curran W. J. Jr, Werner-Wasik M., Camphausen K. A., Hyslop T., Axelrod R., Andrews D. W., Glass J., Machtay M., Dicker A. P., A phase 1b trial of the combination of the antiangiogenic agent sunitinib and radiation therapy for patients with primary and metastatic central nervous system malignancies. Cancer 2011 117 24 5548 5559 2-s2.0-79957903882 10.1002/cncr.26216
125. Chang S. M., Lamborn K. R., Malec M., Larson D., Wara W., Sneed P., Rabbitt J., Page M., Nicholas M. K., Prados M. D., Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme. International Journal of Radiation Oncology, Biology, Physics 2004 60 2 353 357 2-s2.0-4544289953 10.1016/j.ijrobp.2004.04.023 (Pubitemid 39233451)
126. Huang S. M., Bock J. M., Harari P. M., Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Research 1999 59 8 1935 1940 2-s2.0-0033561522 (Pubitemid 29186168)
127. Bonner J. A., Harari P. M., Giralt J., Cohen R. B., Jones C. U., Sur R. K., Raben D., Baselga J., Spencer S. A., Zhu J., Youssoufian H., Rowinsky E. K., Ang K. K., Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. The Lancet Oncology 2010 11 1 21 28 2-s2.0-73249143536 10.1016/S1470-2045(09)70311-0
128. Rudner J., Ruiner C. E., Handrick R., Eibl H. J., Belka C., Jendrossek V., The Akt-inhibitor Erufosine induces apoptotic cell death in prostate cancer cells and increases the short term effects of ionizing radiation. Radiation Oncology 2010 5 1, article 108 2-s2.0-78149493021 10.1186/1748-717X-5-108
129. Prevo R., Deutsch E., Sampson O., Diplexcito J., Cenge K., Harper J., O'Neill P., McKenna W. G., Patel S., Bernhard E. J., Class I PI3 kinase inhibition by the pyridinylfuranopyrimidine inhibitor PI-103 enhances tumor radiosensitivity. Cancer Research 2008 68 14 5915 5923 2-s2.0-48649096069 10.1158/0008-5472.CAN-08-0757
130. Kim I. A., Bae S. S., Fernandes A., Wu J., Muschel R. J., McKenna W. G., Birnbaum M. J., Bernhard E. J., Selective inhibition of Ras, phosphoinositide 3 kinase, and Akt isoforms increases the radiosensitivity of human carcinoma cell lines. Cancer Research 2005 65 17 7902 7910 2-s2.0-24744452428 10.1158/0008-5472.CAN-05-0513 (Pubitemid 41297268)
131. Konstantinidou G., Bey E. A., Rabellino A., Schuster K., Maira M. S., Gazdar A. F., Amici A., Boothman D. A., Scaglioni P. P., Dual phosphoinositide 3-kinase/mammalian target of rapamycin blockade is an effective radiosensitizing strategy for the treatment of non-small cell lung cancer harboring K-RAS mutations. Cancer Research 2009 69 19 7644 7652 2-s2.0-70350228529 10.1158/0008-5472.CAN-09-0823
132. Fokas E., Yoshimura M., Prevo R., Higgins G., Hackl W., Maira S. M., Bernhard E. J., McKenna W. G., Muschel R. J., NVP-BEZ235 and NVP-BGT226, dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitors, enhance tumor and endothelial cell radiosensitivity. Radiation Oncology 2012 7, article 48